TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00998816

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin
Description: pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
Study: NCT04340193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified dose on specified days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE (Trans-arterial ChemoEmbolization)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE (Trans-arterial ChemoEmbolization)
Study: NCT00908674

Intervention type: DRUG
Intervention: Cyproterone acetate (Androcur)
Description: The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).~Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.~Administration period: 12 months.
Study: NCT02078830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Tegaderm™ CHG I.V. Securement Dressing
Description: Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing
Description: Placebo Dressing with the same shape like the CHG-Dressing without CHG.
Study: NCT01616719

Intervention type: DEVICE
Group type: OTHER
Intervention: DTRAX Graft
Description: DTRAX Graft is an allograft implant inserted to support spinal fusion.
Study: NCT04340193

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE (Trans-arterial ChemoEmbolization)
Study: NCT01515007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin dispersion for inhalation
Study: NCT01784380

Intervention type: DRUG
Intervention: Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin
Study: NCT02782988

Intervention type: OTHER
Intervention: olfactory tests, otoacoustic emissions (OAE)
Description: Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.
Study: NCT01515007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01814618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Respules
Description: Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
Study: NCT06091579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil Inhalation Powder
Description: Oral inhalation using a Plastiape capsule-based dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil Inhalation Powder
Description: Oral inhalation using a Plastiape capsule-based dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil Inhalation Powder
Description: Oral inhalation using a Plastiape capsule-based dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil Inhalation Powder
Description: Oral inhalation using a Plastiape capsule-based dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil Inhalation Powder
Description: Oral inhalation using a Plastiape capsule-based dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
Study: NCT02782988

Intervention type: OTHER
Intervention: olfactory tests, otoacoustic emissions (OAE)
Description: Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.

Intervention type: OTHER
Intervention: olfactory tests, otoacoustic emissions (OAE)
Description: Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.
Study: NCT06091579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
Study: NCT04177433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Medrol Injectable Product
Description: Corticosteroid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT01893814

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT02909114

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.~The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT
Study: NCT01532219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Psychodynamic Treatment
Description: Ten weeks of guided self-help + therapist contact, via the Internet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered structured support
Description: Ten weeks of therapist contact, via the Internet.
Study: NCT00715286

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: timing of surgery
Description: Surgery is followed by chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: timing of surgery
Description: Chemotherapy is followed by surgery
Study: NCT00748254

Intervention type: PROCEDURE
Intervention: Laser Based Photoacoustic Tomography, MRI, Ultrasound
Description: Healthy subjects will have scans on finger joints with any of the scanning methods described above.

Intervention type: PROCEDURE
Intervention: laser based photoacoustic tomography, MRI, ultrasound
Description: Subjects with arthritis will have scans on finger joints with any of the scanning methods described above.
Study: NCT03351829

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene-modified autologous stem cells
Description: 1 infusion for 5x10\^6\~1x10\^7 gene-modified cells; or more infusions depending on the circumstances
Study: NCT00577629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375mg/m2 each week x 4 weeks of induction, beginning on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
Study: NCT05419908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT00577629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
Study: NCT03615131

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI-TRUS fusion prostate biopsy
Description: First an advanced MRI prostate image is obtained, annotated and recorded by the Radiology of the Kantonsspital Winterthur. Next, using special fusion technology, the recorded MRI image is fused with a live transrectal ultrasound by the Urologist who performs a MRI/TRUS fusion biopsy.
Study: NCT00273780

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence counseling
Description: Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence counseling
Description: Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alarm device
Description: This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alarm device
Description: This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
Study: NCT01931826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic treatment
Description: The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic treatment
Description: The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total EGDS+ endoscopy
Description: Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
Study: NCT00577629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tositumomab
Description: 450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
Study: NCT03771326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10
Description: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10
Description: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
Study: NCT03912103

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interdisciplinary Deprescribing and Medication Optimization Intervention
Description: as current
Study: NCT04187534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Albumin Fluid Resuscitation Optimization Intervention
Description: Multi-faceted quality improvement intervention to optimize appropriateness of albumin use for fluid resuscitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Practice
Description: Albumin fluid resuscitation according to usual practice
Study: NCT04293991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula
Description: Evaluate the use of HFNC in prevention of intubation in immunocompromised patients adimitted to icu.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Invasive Ventilation
Description: Evaluate the use of HFNC in prevention of intubation in immunocompromised patient admitted to icu.
Study: NCT03017456

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survivorship Care Plan
Description: SCP-Intervention: Patients in the SCP-Int arm will attend a one-time appointment with a trained oncology nurse while the patients in the UC arm will receive care according to the hospital standards for follow-up care. The intervention will be delivered during a regular follow-up appointment, face-to-face and will inform and educate patients on self-management and support as well as promote access to and coordination of post-treatment care. The appointment will focus on empowering the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support. Nurses will integrate a number of active behavior change ingredients including the integration of motivational interviewing techniques which are effective in increasing healthy behaviors.
Study: NCT00052962

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cytoreductive surgery
Description: Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}.
Study: NCT01065805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 18F-FLT
Description: Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.~Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient
Study: NCT06709326

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Apheresis
Description: Isolate tumor cells, immune cells, exosomes and cell free DNA from the blood by a clinically used method of whole blood volume filtration, apheresis, and subsequent separation of blood components using novel techniques, such as acoustophoresis and other experimental protocols.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Isolate tumor cells, immune cells, exosomes and cell free DNA from the blood by a clinically used method of whole blood volume filtration, apheresis, and subsequent separation of blood components using novel techniques, such as acoustophoresis and other experimental protocols.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Isolate tumor cells, immune cells, exosomes and cell free DNA from the blood by a clinically used method of whole blood volume filtration, apheresis, and subsequent separation of blood components using novel techniques, such as acoustophoresis and other experimental protocols.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Apheresis will be performed before initiation of systemic therapy (androgen deprivation therapy) and 4 weeks after. Androgen deprivation therapy is treatment as per clinical routine and not part of the protocol.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anti androgen therapy
Description: Apheresis will be performed before initiation of systemic therapy (anti androgen therapy). Anti androgen therapy is treatment as per clinical routine and not part of the protocol.
Study: NCT00918398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 100 mg iv infusion, single dose, 4 hours infusion
Study: NCT00052962

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cytoreductive surgery
Description: Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)
Description: Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m\^2 cisplatin. Post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluororacil (5-FU) 800 mg/m\^2 and paclitaxel 125 mg/m\^2.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}.
Study: NCT01941069

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping Power Program
Description: The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
Study: NCT03555136

Intervention type: DRUG
Intervention: Vortioxetine
Description: Treatment with vortioxetine as per local SmPC
Study: NCT03372317

Intervention type: DRUG
Intervention: 18F-MK-6240
Description: Results of the 18F-MK-6240 PET scan will be correlated with other observations.
Study: NCT01937689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
Study: NCT02377349

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Boostrix™
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
Study: NCT02152865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupeol
Description: Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control vehicle
Description: Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks
Study: NCT01818622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue-blocking goggles/screens
Description: Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue-blocking goggles/screens
Description: Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Clear-lensed goggles
Description: Clear lensed safety eyewear. Patients may choose model for best comfort.
Study: NCT00112151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LowT
Description: Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LowT
Description: Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Weight training 45-60 minutes 3 times per week
Study: NCT02377349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
Study: NCT02361736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch
Description: 6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lactate Ringers
Description: Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery